Inhibitory action of telithromycin against Shiga toxin and endotoxin

Biochemical and Biophysical Research Communications

Volumn 310, Issue 4, 2003, Pages 1194-1199

  Nakagawa, Saori ^a   Kojio, Seiichi ^a   Taneike, Ikue ^a   Iwakura, Nobuhiro ^a   Tamura, Yukiko ^a   Kushiya, Koji ^a   Gondaira, Fumio ^a   Yamamoto, Tatsuo ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Cytokine; Endotoxin; Escherichia coli; Phage; Shiga toxin; Telithromycin

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; BACTERIUM LIPOPOLYSACCHARIDE; CLARITHROMYCIN; ERYTHROMYCIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; KETOLIDE; NORFLOXACIN; ROXITHROMYCIN; SHIGA TOXIN; TELITHROMYCIN;

ADULT; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIOPHAGE; BLOOD; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG SELECTIVITY; ESCHERICHIA COLI; GROWTH INHIBITION; HUMAN; HUMAN CELL; INFLAMMATION; MONOCYTE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

EID: 0141927188     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2003.09.145     Document Type: Article

References (30)

1. Denis A., Agouridas C., Auger J.M., Benedetti Y., Bonnefoy A., Bretin F., Chantot J.F., Dussarat A., Fromentin C., D'Ambrieres S.G., Lachaud S., Laurin P., Le Martret O., Loyau V., Tessot N., Pejac J.M., Perron S. Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. Bioorg. Med. Chem. Lett. 9:1999;3075-3080.
2. Jalava J., Kataja J., Seppala H., Huovinen P. In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species. Antimicrob. Agents Chemother. 45:2001;789-793.
3. Khan A.A., Slifer T.R., Araujo F.G., Remington J.S. Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. Int. J. Antimicrob. Agents. 11:1999;121-132.
4. Watanabe H., Wada A., Inagaki Y., Ito K., Tamura K. Outbreaks of enterohaemorrhagic Escherichia coli O157:H7 infection by two different genotype strains in Japan. Lancet. 348:1996;831-832.
5. Kaper J.B., O'Brien A.D. Escherichia coli O157:H7 and Other Shiga Toxin-producing E. coli Strains. 1998;American Society for Microbiology (ASM) press, Washington, DC.
6. Pickering L.K., Obrig T.G., Stapleton F.B. Hemolytic-uremic syndrome and enterohemorrhagic Escherichia coli. Pediatr. Infect. Dis. J. 13:1994;459-475.
7. American Gastroenterological Association, Consensus conference statement: Escherichia coli O157:H7 infections-an emerging national health crisis, July 11-13, 1994, Gastroenterology 108 (1995) 1923-1934.
8. Inward C.D., Varagunam M., Adu D., Milford D.V., Taylor C.M. Cytokines in haemolytic uraemic syndrome associated with verocytotoxin-producing Escherichia coli infection. Arch. Dis. Child. 77:1997;145-147.
9. Proulx F., Turgeon J.P., Litalien C., Mariscalco M.M., Robitaille P., Seidman E. Inflammatory mediators in Escherichia coli O157:H7 hemorrhagic colitis and hemolytic-uremic syndrome. Pediatr. Infect. Dis. J. 17:1998;899-904.
10. Litalien C., Proulx F., Mariscalco M.M., Robitaille P., Turgeon J.P., Orrbine E., Rowe P.C., McLaine P.N., Seidman E. Circulating inflammatory cytokine levels in hemolytic uremic syndrome. Pediatr. Nephrol. 13:1999;840-845.
11. O' Brien A.D., Newland J.W., Miller S.F., Holmes R.K. Shiga-like toxin-converting phages from Escherichia coli strains that cause hemorrhagic colitis or infantile diarrhea. Science. 226:1984;694-696.
12. Matsushiro A., Sato K., Miyamoto H., Yamamura T., Honda T. Induction of prophages of enterohemorrhagic Escherichia coli O157:H7 with norfloxacin. J. Bacteriol. 181:1999;2257-2260.
13. Zhang X., McDaniel A.D., Wolf L.E., Keusch G.T., Waldor M.K., Acheson D.W.K. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J. Infect. Dis. 181:2000;664-670.
14. Food Sanitation Division Environmental Health Bureau Ministry of Health and Welfare, Japan, Report on enterohemorrhagic Escherichia coli O157 infections, 1997.
15. Yamamoto T., Taneike I., Tamura Y., Nishi J., Kawakami K. A novel hemagglutinin of enterohemorrhagic Escherichia coli O86:NM associated with hemolytic uremic syndrome in a child. Acta Med. Biol. 48:2000;147-152.
16. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial susceptibility testing, 12th informational supplement, National Committee for Clinical Laboratory Standards, Wayne, PA, 2002, P M100-S12.
17. Nataro J.P., Kaper J.B. Diarrheagenic Escherichia coli. Clin. Microbiol. Rev. 11:1998;142-201.
18. Yutsudo T., Nakabayashi N., Hirayama T., Takeda Y. Purification and some properties of a Vero toxin from Escherichia coli O157:H7 that is immunologically unrelated to Shiga toxin. Microb. Pathog. 3:1987;21-30.
19. Zhang H.M., Ou Z.L., Gondaira F., Ohmura M., Kojio S., Yamamoto T. Protective effect of anisodamine against Shiga toxin-1: inhibition of cytokine production and increase in the survival of mice. J. Lab. Clin. Med. 137:2001;93-100.
20. Mustard J.A., Little J.W. Analysis of Escherichia coli RecA interactions with LexA, lambda CI, and UmuD by site-directed mutagenesis of recA. J. Bacteriol. 182:2000;1659-1670.
21. Champney W.S., Pelt J. Telithromycin inhibition of protein synthesis and 50S ribosomal subunit formation in Streptococcus pneumoniae cells. Curr. Microbiol. 45:2002;328-333.
22. Westerholt S., Hartung T., Tollens M., Gustrau A., Oberhoffer M., Karch H., Klare B., Pfeffer K., Emmrich P., Oberhoffer R. Inflammatory and immunological parameters in children with haemolytic uremic syndrome (HUS) and gastroenteritis-pathophysiological and diagnostic clues. Cytokines. 12:2000;822-827.
23. Yagi H., Narita N., Matsumoto M., Sakurai Y., Ikari H., Yoshioka A., Kita E., Ikeda Y., Titani K., Fujimura Y. Enhanced low shear stress induced platelet aggregation by Shiga-like toxin 1 purified from Escherichia coli O157. Am. J. Hematol. 66:2001;105-115.
24. Duong M., Simard M., Bergeron Y., Bergeron M.G. Kinetic study of the inflammatory response in Streptococcus pneumoniae experimental pneumonia treated with the ketolide HMR 3004. Antimicrob. Agents Chemother. 45:2001;252-262.
25. Vazifeh D., Abdelghaffar H., Labro M.T. Cellular accumulation of the new ketolide RU 64004 by human neutrophils: comparison with that of azithromycin and roxithromycin. Antimicrob. Agents Chemother. 41:1997;2099-2107.
26. Vazifeh D., Preira A., Bryskier A., Labro M.T. Interactions between HMR 3647, a new ketolide, and human polymorphonuclear neutrophils. Antimicrob. Agents Chemother. 42:1998;1944-1951.
27. Zhanel G.G., Walters M., Noreddin A., Vercaigne L.M., Wierzbowski A., Embil J.M., Gin A.S., Douthwaite S., Hoban D.J. The ketolides: a critical review. Drugs. 62:2002;1771-1804.
28. Gladue R.P., Snider M.E. Intracellular accumulation of azithromycin by cultured human fibroblasts. Antimicrob. Agents Chemother. 34:1990;1056-1060.
29. Sack D.A., Lyke C., McLaughlim C., Suwanvanichkij V. Review of Campylobacter jejuni. Sack D.A., Lyke C., McLaughlim C., Suwanvanichkij V. Antimicrobial Resistance in Shigellosis, Cholera and Campylobacteriosis. 2001;31-40 World Health Organization, Geneva.
30. Wagner J., Jabbusch M., Eisenblatter M., Hahn H., Wendt C., Ignatius R. Susceptibilities of Campylobacter jejuni isolates from Germany to ciprofloxacin, moxifloxacin, erythromycin, clindamycin, and tetracycline. Antimicrob. Agents Chemother. 47:2003;2358-2361.